RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Jessica B. Casaletto(Relay Therapeutics (United States))
Cited by 115
Related Papers
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
|Clinical Cancer Research|2023|40
Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors
|Clinical Cancer Research|2020|29